<DOC>
	<DOCNO>NCT00060346</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Combining rituximab combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together combination chemotherapy work treat patient newly diagnose Waldenstrom 's macroglobulinemia .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Treating Patients With Newly Diagnosed Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient newly diagnose Waldenstrom 's macroglobulinemia treat rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone . - Determine associate toxic effect regimen , specifically frequency febrile neutropenia , patient . - Determine progression-free survival patient treat regimen . - Correlate baseline cytogenetic feature gene expression profile response patient treat regimen . OUTLINE : This pilot , multicenter study . Patients receive rituximab intravenously ( IV ) approximately 4 hour , cyclophosphamide IV 5-30 minute , doxorubicin IV 5-15 minute , vincristine IV 1 minute day 1 . Patients also receive oral prednisone day 1-5 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually 5 year . ACTUAL ACCRUAL : A total 16 patient accrue study .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis Waldenstrom 's macroglobulinemia confirm presence following : Bone marrow lymphoplasmacytosis : &gt; 10 % lymphoplasmacytic cell OR aggregate sheet one following : lymphocyte , plasma cell lymphoplasmacytic cell bone marrow biopsy ( measure within 4 week prior registration ) Measurable disease define quantitative immunoglobulin M ( IgM ) monoclonal protein &gt; 1,000 mg/dL obtain within 4 week prior registration Cluster differentiation 20 ( CD20 ) positive stain bone marrow lymph node sample obtain &lt; 8 week prior registration Impaired bone marrow function due infiltration lymphoplasmacytic lymphoma , define 1 following : Hemoglobin great 11 g/dL Serum viscosity level relative water least 4.0 centipoise Absolute neutrophil count least 1,000/mm^3 Platelet count least 75,000/mm^3 Bilirubin great 3.0 mg/dL Aspartate aminotransferase ( AST ) great 3 time upper limit normal Creatinine great 3.0 mg/dL Age 18 ECOG ( Eastern Cooperative Oncology Group ) performance status 01 Must symptomatic 1 following : Clinically significant anemia ( hemoglobin great 11 g/dL ) Bulky lymphadenopathy Symptoms attributable hyperviscosity ( e.g. , nose bleeding , gingival bleeding , retinal hemorrhage ) History heart disease allow 1 follow demonstrate echocardiography , multigated acquisition scan ( MUGA ) , exercise MUGA , coronary catheterization : Ejection fraction least 45 % Normal fractional shortening leave ventricle Must test hepatitis B surface antigen within 2 week registration Negative pregnancy test Fertile patient must use effective contraception EXCLUSION CRITERIA : Prior treatment Waldenstrom 's macroglobulinemia Prior antiCD20 therapy Concurrent steroid exceed 10 mg prednisone ( equivalent ) per day Prior irradiation le 4 week elapse prior registration date last treatment Prior anthracyclines Prior malignancy except curatively treat basal cell squamous cell carcinoma skin , carcinoma situ cervix , cancer curatively treat surgery alone patient disease free least 5 year Active heart disease Pregnant nursing Myocardial infarction within past 3 month Congestive heart failure Symptomatic ventricular arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>Rituximab</keyword>
	<keyword>CHOP</keyword>
</DOC>